
ELVN Stock Forecast & Price Target
ELVN Analyst Ratings
Bulls say
Enliven Therapeutics is well-positioned to execute their CML Phase 3 program with ELVN-001, a next-generation ATP-competitive BCR-ABL TKI for chronic myeloid leukemia. With a positive update from the ongoing ENABLE study and FDA Fast Track Designation, the company continues to make progress towards study start in 2H26. Backed by a strong cash position of $895M and expected cash runway into 2030, our financial model reflects solid potential for positive returns, reinforcing our BUY rating and a price target of $78.
Bears say
Enliven Therapeutics is likely to face significant risks, including potential R&D, regulatory, and commercial setbacks, increased competition in the market, and insufficient product sales. Additionally, the company may need to rely on dilutive financing in the future, which could negatively impact financial performance. Based on a DCF-based valuation using a 11% discount rate and a 1.0% terminal growth rate, our price objective for the company is $65 per share, reflecting a total firm value of $3.66B. However, there are uncertainties and risks associated with ELVN-001's clinical development and potential approval, which could impact the company's stock performance.
This aggregate rating is based on analysts' research of Enliven Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ELVN Analyst Forecast & Price Prediction
Start investing in ELVN
Order type
Buy in
Order amount
Est. shares
0 shares